neoSurgical Inc. has hit the 8000 procedure milestone for its FDA-cleared neoClose® device in the United States.
As recently as January we covered the news that neoSurgical was to start a Postmarket Surveillance Study of its FDA-cleared device, neoClose®, comparing it against standard closure technique. The context was that clinical studies suggest port-site hernia incidence is often “grossly under-diagnosed” and “highly prevalent” after Lap and Robotic surgeries, which can lead to a self-perpetuating cycle of repeat surgical interventions and hernia repairs.
neoSurgical® is a commercial-stage company focused on being a global leader in the development of innovative surgical products. The company’s initial product is neoClose®, approved for sale in the US and Europe and designed to be the new standard for Lap surgery port site closure, a potential $300 million opportunity, which looks to be within its sights, given the achievement of the 8000 procedure milestone this early in its lifetime.
“Surgeons in hospitals across the United States are rapidly adopting our neoClose® device because neoClose® is designed to be to the standard of care for closing port sites — a standard that absolutely must be improved to enhance patient outcomes and safety,” said Barry Russell, CEO of neoSurgical.
Source: neoSurgical, Inc